KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE)
KBIO
KBIO was delisted on the 16th of December, 2015.
50 hedge funds and large institutions have $87.9M invested in KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) in 2013 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 21 increasing their positions, 10 reducing their positions, and 5 closing their positions.
220% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 5
110% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 10
28% more funds holding
Funds holding: 39 → 50 (+11)
26% more capital invested
Capital invested by funds: $69.9M → $87.9M (+$18M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$8.12M |
| 2 |
JP Morgan Chase
New York
|
+$7.39M |
| 3 |
Primecap Management
Pasadena,
California
|
+$5.84M |
| 4 |
First Eagle Investment Management
New York
|
+$4.98M |
| 5 |
CCP
Clough Capital Partners
Boston,
Massachusetts
|
+$2.28M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AWMDMG
Austin W. Marxe & David M. Greenhouse
New York
|
-$1.5M |
| 2 |
LBH
Lehman Brothers Holdings
New York
|
-$711K |
| 3 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$530K |
| 4 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
-$170K |
| 5 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
-$92.1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
RhumbLine Advisers
Boston,
Massachusetts
| – | -$57K | -1,253 | Closed |
|
|
SO
52
STRS Ohio
Columbus,
Ohio
| – | -$25.5K | -559 | Closed |
|
|
BJ
53
BlackRock Japan
Tokyo,
Japan
| – | -$3K | -64 | Closed |
|
54
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$1.69K | -37 | -74% |
|
|
RFC
55
Russell Frank Company
Seattle,
Washington
| – | +$273 | +6 | New |
|
KBIO Hedge Fund Activity: Q3 2013 in Review
50 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) (KBIO) for Q3 2013, worth a combined $87.9M — up 26% from $69.9M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new KBIO positions and 5 closed out — a net gain of 11 holders — while 21 added to existing stakes and 10 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $8.12M. The largest seller was Austin W. Marxe & David M. Greenhouse, exiting entirely with an estimated $1.5M sold.
- 50 institutional investors held KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) (KBIO) as of Q3 2013, up from 39 in Q2 2013.
- Funds reported $87.9M of KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) stock for Q3 2013, up 26% quarter-over-quarter.
- 16 funds opened new KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) positions in Q3 2013 and 5 closed out, a net change of +11 holders.
- The largest KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) buyer in Q3 2013 was Fidelity Investments, an estimated $8.12M added.
- The largest KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) seller in Q3 2013 was Austin W. Marxe & David M. Greenhouse, an estimated $1.5M sold.
Based on aggregated 13F filings for Q3 2013.